Compare Cintas Corporation (CTAS) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cintas Corporation vs Zimmer Biomet Holdings Inc — how do they compare? Cintas Corporation trades at $202.32 (market cap $79.86B), while Zimmer Biomet Holdings Inc trades at $88.71 (market cap $16.95B). The key difference: Cintas Corporation is far larger — about 4.7× Zimmer Biomet Holdings Inc's market cap, and Zimmer Biomet Holdings Inc pays the higher dividend (1.08%). Which is the better fit depends on your goals — on Pluang, investors hold Cintas Corporation for 124 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| CTAS | ZBH | |
|---|---|---|
Market Cap | $79.86B | $16.95B |
Volume | 1,323,583 | 2,505,240 |
Sector | Industrials | Health |
52-Week High | $216.53 | $103.98 |
52-Week Low | $163.55 | $79.58 |
Typical Hold Time | 124 Days | 89 Days |
Enterprise Value | $82.33B | $24.02B |
Dividend Yield | 1.03% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cintas (CTAS) trades at $201.87, up 2.37% today, reflecting strong momentum after Q1 2027 earnings beat. The stock shows bullish technical signals with support near $195 and resistance at $200. Fundamentals are robust with revenue growth to $10.34B in 2025, net margin of 17.82%, and rising profitability. Recent news highlights raised guidance and record quarterly revenue exceeding $3B, signaling operational strength.
Outlook remains positive driven by organic growth and margin expansion, but high valuation multiples (P/E 39.67) pose a risk if growth slows. Analyst consensus is Moderate Buy with a $234.60 price target, implying 16% upside. Key risks include economic sensitivity and competitive pressures in uniform services.
Zimmer Biomet (ZBH) trades at $88.70, up 0.24% on the day, with a bearish technical outlook but strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.07 exceeding expectations. Revenue growth remains steady, reaching $8.23B in 2025, while profitability metrics like a 69.87% gross margin and 9.48% net margin reflect operational efficiency. Recent corporate news includes a $0.24 quarterly dividend declaration and leadership promotions aimed at accelerating commercial transformation.
The investment outlook is mixed, with analyst consensus leaning hold (52.38%) but a price target of $103.11 suggesting 16% upside. Key opportunities include sustained earnings beats and strategic initiatives, while risks involve rising debt levels, competitive pressures, and technical bearish signals. The stock's current valuation at a P/E of 21.57 appears reasonable relative to growth prospects, but investors should weigh fundamental strength against near-term technical weakness and macroeconomic headwinds in the healthcare sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cintas Corporation
In its core uniform and facility services unit (78% of sales), Cintas provides uniform rental programs to businesses across the size spectrum, mostly in North America. The firm is by far the largest provider in the industry. Facilities products generally include the rental and sale of entrance mat, mops, shop towels, hand sanitizers, and restroom supplies. Cintas also runs a first aid and safety services business (11% of sales), a fire protection services business (7% of sales), and a uniform direct sales business (4% of sales).
Read more on CTAS →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
